Damora Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DMRA Nasdaq 2834 www.damoratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Damora Therapeutics, Inc.

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - May 12th, 2026 2:05 pm
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders - May 8th, 2026 3:30 pm
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer - May 5th, 2026 11:05 am
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum - May 5th, 2026 8:10 am
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2026 6:00 am
Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says - Apr 24th, 2026 9:54 am
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now? - Apr 20th, 2026 10:00 am
How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1% - Apr 10th, 2026 7:55 am
Damora Therapeutics (DMRA) Overhauls Leadership: Is Its Capital Strategy About To Quietly Shift? - Apr 1st, 2026 6:18 am
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors - Mar 23rd, 2026 6:00 am
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - Mar 19th, 2026 2:10 pm